Please login to the form below

Not currently logged in
Email:
Password:

brigatinib

This page shows the latest brigatinib news and features for those working in and with pharma, biotech and healthcare.

Modest meeting sees only two drugs recommended by CHMP

Modest meeting sees only two drugs recommended by CHMP

Also picking up label extensions were Takeda’s Alunbrug (brigatinib), Boehringer Ingelheim’s Ofev (nintedanib) and Amgen’s Otezla (apremilast).

Latest news

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase ... Company acquisition. Rare diseases, option

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page

For those who can imagine better, Page & Page is home to meaningful encounters of a marketing, communication and creative kind:...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics